Altimmune, Inc.
NASDAQAltimmune enters the final stretch of September with a curious split: its short interest remains one of the heaviest in small-cap biotech, yet the bears have been quietly retreating all week while the stock quietly climbs. The core tension here is scale vs. direction. Short interest is still enormous — nearly 47% of the free float, a level that would dominate the conversation for…
Snapshot as of 10 Oct 2026
Altimmune enters the final stretch of September with a curious split: its short interest remains one of the heaviest in small-cap biotech, yet the bears have been quietly retreating all week while the stock quietly…
Altimmune heads into the post-earnings period with nearly half its float sold short and a lending market that has loosened sharply — a combination that makes the stock one of the more structurally charged setups in…
Altimmune enters July with one of the most heavily shorted positions in small-cap biotech, even as the stock edges higher and insiders continue to put their own money in. Short interest is the defining story here, and…
Altimmune enters the back half of May with its highest-conviction clinical catalyst in years, yet short sellers have barely flinched — a striking standoff between data momentum and a deeply entrenched bear camp. Short…
Altimmune just reported Q1 results, beat its EPS estimate, and simultaneously saw short sellers add aggressively — a setup that puts the stock in a genuinely unusual position heading into what comes next. The short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALT — free to start on ORTEX.
Sign up for free →Open ALT on ORTEX